It would be easy to say shares of Clorox (NYSE: CLX) have already enjoyed their proverbial day in the sun. The stock rallied 46% between the end of February and early September when the COVID-19 pandemic made Clorox-branded disinfectant products the world's most marketable goods. But, with the world adjusted and a coronavirus vaccine (or vaccines) on the horizon, there seems little upside left to tap. Shares have fallen 14% from their September peak, in fact, in step with the curbing of the COVID-19 panic.
But Clorox has a solid second act in store for a post-COVID world. A relatively new -- but highly experienced -- CEO has already demonstrated a clear understanding of the modern marketplace and how her company can succeed in it.
Image source: Getty Images.
Source Fool.com